A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine (HFEM)

To evaluate the efficacy of two distinct doses of subcutaneous LBR-101 in the preventive treatment of HFEM, measured by mean change from baseline in the monthly migraine days during the 28-day post treatment period ending with week 12.

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Maria Coburn
(650) 736-9551